Sidoti Equities Analysts Cut Earnings Estimates for PRE

Prenetics Global Limited (NASDAQ:PRE) – Analysts at Sidoti reduced their Q3 2027 earnings per share estimates for Prenetics Global in a report released on Friday, February 20th. Sidoti analyst A. Hantman now anticipates that the company will post earnings of $0.71 per share for the quarter, down from their prior estimate of $0.76. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2027 earnings at $1.19 EPS and FY2027 earnings at $1.65 EPS.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings results on Wednesday, February 18th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.22. Prenetics Global had a negative return on equity of 19.07% and a negative net margin of 61.33%.The business had revenue of $36.60 million for the quarter, compared to analyst estimates of $36.15 million.

A number of other analysts also recently issued reports on the stock. Cantor Fitzgerald raised their price target on shares of Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Roth Mkm began coverage on Prenetics Global in a research note on Wednesday, February 11th. They set a “buy” rating and a $36.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $34.00.

Prenetics Global Price Performance

NASDAQ:PRE opened at $15.61 on Monday. The firm has a market capitalization of $262.72 million, a price-to-earnings ratio of -3.88 and a beta of 0.35. The company’s 50-day moving average is $17.82 and its two-hundred day moving average is $14.12. Prenetics Global has a 1-year low of $3.09 and a 1-year high of $22.86.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new stake in Prenetics Global during the 4th quarter worth approximately $1,302,000. 683 Capital Management LLC purchased a new position in Prenetics Global in the 4th quarter valued at approximately $1,181,000. Aberdeen Group plc acquired a new position in shares of Prenetics Global in the third quarter worth $979,000. Millennium Management LLC purchased a new stake in shares of Prenetics Global during the fourth quarter worth $810,000. Finally, Marshall Wace LLP acquired a new stake in shares of Prenetics Global in the fourth quarter valued at $788,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.